In BLISS-76, 43.2% (118/273) of the high-dose belimumab group compared with 33.8% (93/275) of the placebo group achieved the primary endpoint at week 52. 7 This difference, although modest in ...

Infusion reaction rates were somewhat higher in groups treated with belimumab. In the BLISS-76 study, patients were divided into three different groups (as in BLISS-52): belimumab 1 mg/kg ...